{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:48:12Z","timestamp":1780984092551,"version":"3.54.1"},"reference-count":82,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1053\/j.ajkd.2009.06.004","type":"journal-article","created":{"date-parts":[[2009,8,19]],"date-time":"2009-08-19T04:21:38Z","timestamp":1250655698000},"page":"619-637","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":140,"title":["Benefits and Harms of Phosphate Binders in CKD: A Systematic Review of Randomized Controlled Trials"],"prefix":"10.1053","volume":"54","author":[{"given":"Sankar D.","family":"Navaneethan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suetonia C.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C.","family":"Craig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grahame J.","family":"Elder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni F.M.","family":"Strippoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.ajkd.2009.06.004_bib2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ki.2008.130","article-title":"Hyperphosphatemia of chronic kidney disease","volume":"74","author":"Hruska","year":"2008","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2009.06.004_bib3","first-page":"5","article-title":"Pathogenesis of parathyroid hyperplasia in renal failure","volume":"18","author":"Cozzolino","year":"2005","journal-title":"J Nephrol"},{"key":"10.1053\/j.ajkd.2009.06.004_bib4","doi-asserted-by":"crossref","first-page":"119","DOI":"10.5414\/CNP63119","article-title":"Cellular and molecular mechanisms of secondary hyperparathyroidism","volume":"63","author":"Silver","year":"2005","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.ajkd.2009.06.004_bib5","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","article-title":"Association of serum phosphorus and calcium \u00d7 phosphate product with mortality risk in chronic hemodialysis patients: A national study","volume":"31","author":"Block","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2009.06.004_bib6","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1053\/j.ajkd.2008.03.020","article-title":"Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"52","author":"Tentori","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2009.06.004_bib7","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2009.06.004_bib8","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1161\/01.CIR.103.7.987","article-title":"Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure","volume":"103","author":"Guerin","year":"2001","journal-title":"Circulation"},{"key":"10.1053\/j.ajkd.2009.06.004_bib9","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1097\/01.ASN.0000113243.24155.2F","article-title":"Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: Evidence for the complexity of the association between mineral metabolism and outcomes","volume":"15","author":"Stevens","year":"2004","journal-title":"J Am Soc Nephrol"},{"issue":"suppl 2","key":"10.1053\/j.ajkd.2009.06.004_bib10","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1681\/ASN.2005060663","article-title":"Control of hyperphosphatemia among patients with ESRD","volume":"16","author":"Coladonato","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2009.06.004_bib11","article-title":"Management of chronic kidney disease mineral-bone disorder","volume":"14","author":"Fadem","year":"2007","journal-title":"Adv Chronic Kidney Dis"},{"issue":"suppl 3","key":"10.1053\/j.ajkd.2009.06.004_bib12","first-page":"S70","article-title":"Guideline 5: Use of phosphate binders in CKD, in K\/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease Patients","volume":"42","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2009.06.004_bib13","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1038\/sj.ki.5001997","article-title":"A new era in phosphate binder therapy: What are the options?","volume":"105","author":"Salusky","year":"2006","journal-title":"Kidney Int Suppl"},{"key":"10.1053\/j.ajkd.2009.06.004_bib14","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1185\/030079907X242719","article-title":"A comparative review of the efficacy and safety of established phosphate binders: Calcium, sevelamer, and lanthanum carbonate","volume":"23","author":"Sprague","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1053\/j.ajkd.2009.06.004_bib15","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/bmj.309.6964.1286","article-title":"Identifying relevant studies for systematic reviews","volume":"309","author":"Dickersin","year":"1994","journal-title":"BMJ"},{"key":"10.1053\/j.ajkd.2009.06.004_bib16","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0140-6736(99)04149-5","article-title":"Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement","volume":"354","author":"Moher","year":"1999","journal-title":"Lancet"},{"key":"10.1053\/j.ajkd.2009.06.004_bib17","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"key":"10.1053\/j.ajkd.2009.06.004_bib18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1053\/j.ajkd.2009.06.004_bib19","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1053\/j.ajkd.2009.06.004_bib20","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1159\/000168713","article-title":"Calcium acetate versus calcium carbonate for the control of serum phosphorus in hemodialysis patients","volume":"14","author":"Almirall","year":"1994","journal-title":"Am J Nephrol"},{"key":"10.1053\/j.ajkd.2009.06.004_bib21","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/ajkd.1998.v31.pm9469496","article-title":"Randomized crossover study comparing the phosphate-binding efficacy of calcium ketoglutarate versus calcium carbonate in patients on chronic hemodialysis","volume":"31","author":"Bro","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2009.06.004_bib22","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1093\/ndt\/14.6.1475","article-title":"Calcium ketoglutarate versus calcium acetate for treatment of hyperphosphataemia in patients on maintenance haemodialysis: A cross-over study","volume":"14","author":"Birck","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2009.06.004_bib23","first-page":"348","article-title":"A comparison of phosphorus-chelating effect of calcium carbonate versus calcium acetate before dialysis","volume":"20","author":"Borrego","year":"2000","journal-title":"Nefrologia"},{"key":"10.1053\/j.ajkd.2009.06.004_bib24","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1159\/000186802","article-title":"Calcium acetate versus calcium carbonate as phosphate binders in hemodialysis patients","volume":"60","author":"Caravaca","year":"1992","journal-title":"Nephron"},{"key":"10.1053\/j.ajkd.2009.06.004_bib25","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S0272-6386(12)80496-3","article-title":"Calcium acetate control of serum phosphorus in hemodialysis patients","volume":"17","author":"Emmett","year":"1991","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2009.06.004_bib26","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1590\/S1516-31802000000600006","article-title":"Calcium acetate versus calcium carbonate in the control of hyperphosphatemia in hemodialysis patients","volume":"118","author":"d'Almeida Filho","year":"2000","journal-title":"Sao Paulo Med J"},{"key":"10.1053\/j.ajkd.2009.06.004_bib27","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1159\/000065273","article-title":"Metabolic and skeletal effects of low and high doses of calcium acetate in patients with preterminal chronic renal failure","volume":"22","author":"Phelps","year":"2002","journal-title":"Am J Nephrol"},{"key":"10.1053\/j.ajkd.2009.06.004_bib28","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/ndt\/9.8.1121","article-title":"Calcium acetate versus calcium carbonate as phosphate-binding agents in chronic haemodialysis","volume":"9","author":"Pflanz","year":"1994","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2009.06.004_bib29","first-page":"341","article-title":"Calcium acetate versus calcium carbonate as phosphorus binders in patients on chronic haemodialysis: A controlled study","volume":"8","author":"Ring","year":"1993","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2009.06.004_bib30","first-page":"130","article-title":"Effect of oral calcium on noninvasive indices of bone formation and bone mass in hemodialysis patients: A randomized double-blind placebo-controlled study","volume":"20","author":"Rudnicki","year":"1994","journal-title":"Miner Electrolyte Metab"},{"key":"10.1053\/j.ajkd.2009.06.004_bib31","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/ndt\/6.3.170","article-title":"The treatment of uraemic hyperphosphataemia with calcium acetate and calcium carbonate: A comparative study","volume":"6","author":"Schaefer","year":"1991","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2009.06.004_bib32","doi-asserted-by":"crossref","first-page":"c273","DOI":"10.1159\/000170783","article-title":"Phosphate binder impact on bone remodeling and coronary calcification\u2014Results from the BRiC Study","volume":"110","author":"Barreto","year":"2008","journal-title":"Nephron Clin Pract"},{"key":"10.1053\/j.ajkd.2009.06.004_bib33","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S0272-6386(99)70221-0","article-title":"A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients","volume":"33","author":"Bleyer","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2009.06.004_bib34","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1111\/j.1523-1755.2005.00600.x","article-title":"Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis","volume":"68","author":"Block","year":"2005","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2009.06.004_bib35","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1053\/j.ajkd.2008.02.298","article-title":"A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: The Calcium Acetate Renagel Evaluation-2 (CARE-2) study","volume":"51","author":"Qunibi","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2009.06.004_bib36","first-page":"18","article-title":"A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium","volume":"51","author":"Chertow","year":"1999","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.ajkd.2009.06.004_bib37","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1523-1755.2002.00434.x","article-title":"Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients","volume":"62","author":"Chertow","year":"2002","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2009.06.004_bib38","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/sj.ki.5002466","article-title":"Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients","volume":"72","author":"Suki","year":"2007","journal-title":"Kidney Int"},{"issue":"suppl 9","key":"10.1053\/j.ajkd.2009.06.004_bib39","first-page":"S108","article-title":"Sevelamer worsens metabolic acidosis in hemodialysis patients","volume":"199","author":"DeSanto","year":"2006","journal-title":"J Nephrol"},{"key":"10.1053\/j.ajkd.2009.06.004_bib40","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/ndt\/gfn488","article-title":"Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis","volume":"24","author":"Evenepoel","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2009.06.004_bib41","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1681\/ASN.2006101089","article-title":"Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients","volume":"19","author":"Ferreira","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2009.06.004_bib42","first-page":"755A","article-title":"Effects of PB-94 (sevelamer hydrochloride), a phosphate binder, on the treatment of hyperphosphatemia in hemodialysis patients\u2014A randomized, open label, dose titration study of PB-94 versus Caltan tablet 500 (calcium carbonate)","volume":"12","author":"Kingusa","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2009.06.004_bib43","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1046\/j.1523-1755.63.s85.17.x","article-title":"Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: A comparison with calcium acetate","volume":"85","author":"Hervas","year":"2003","journal-title":"Kidney Int Suppl"},{"key":"10.1053\/j.ajkd.2009.06.004_bib44","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1744-9987.2005.00294.x","article-title":"Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan","volume":"9","author":"Koiwa","year":"2005","journal-title":"Ther Apher Dial"},{"key":"10.1053\/j.ajkd.2009.06.004_bib45","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1111\/j.1523-1755.2004.00590.x","article-title":"Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study)","volume":"65","author":"Qunibi","year":"2004","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2009.06.004_bib46","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/sj.ki.5002518","article-title":"The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer","volume":"72","author":"Russo","year":"2007","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2009.06.004_bib47","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/ndt\/18.3.582","article-title":"Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: An open-label, randomized study","volume":"18","author":"Sadek","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2009.06.004_bib48","first-page":"785","article-title":"Efficacy and safety of sevelamer","volume":"25","author":"Shaheen","year":"2004","journal-title":"Saudi Med J"},{"key":"10.1053\/j.ajkd.2009.06.004_bib49","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0272-6386(97)90009-3","article-title":"Poly[allylamine hydrochloride](RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure","volume":"29","author":"Chertow","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2009.06.004_bib50","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1046\/j.1523-1755.63.s85.18.x","article-title":"A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients","volume":"85","author":"D'Haese","year":"2003","journal-title":"Kidney Int Suppl"},{"key":"10.1053\/j.ajkd.2009.06.004_bib51","doi-asserted-by":"crossref","first-page":"c8","DOI":"10.1159\/000084653","article-title":"Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: A 6-month, randomized, comparative trial versus calcium carbonate","volume":"100","author":"Hutchison","year":"2005","journal-title":"Nephron Clin Pract"},{"key":"10.1053\/j.ajkd.2009.06.004_bib52","doi-asserted-by":"crossref","first-page":"404","DOI":"10.5414\/CNP70404","article-title":"Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia","volume":"70","author":"Shigematsu","year":"2008","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.ajkd.2009.06.004_bib53","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1093\/ndt\/gfl146","article-title":"Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow up","volume":"21","author":"Spasovski","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2009.06.004_bib54","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/ndt\/gfh693","article-title":"Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study","volume":"20","author":"Al-Baaj","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2009.06.004_bib55","doi-asserted-by":"crossref","first-page":"461","DOI":"10.5414\/CNP63461","article-title":"Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease","volume":"63","author":"Chiang","year":"2005","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.ajkd.2009.06.004_bib56","doi-asserted-by":"crossref","first-page":"193","DOI":"10.5414\/CNP62193","article-title":"Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis","volume":"62","author":"Finn","year":"2004","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.ajkd.2009.06.004_bib57","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0272-6386(03)00554-7","article-title":"Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: A new phosphate binder for the treatment of hyperphosphatemia","volume":"42","author":"Joy","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2009.06.004_bib58","first-page":"284","article-title":"Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years","volume":"70","author":"Malluche","year":"2008","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.ajkd.2009.06.004_bib59","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.2215\/CJN.04741107","article-title":"Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: A multicenter study","volume":"3","author":"Mehrotra","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2009.06.004_bib60","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/sj.ki.5002059","article-title":"Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients","volume":"71","author":"Block","year":"2007","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2009.06.004_bib61","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1093\/ndt\/gfh894","article-title":"Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density","volume":"20","author":"Asmus","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2009.06.004_bib62","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1359\/JBMR.041221","article-title":"Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis","volume":"20","author":"Raggi","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1053\/j.ajkd.2009.06.004_bib63","doi-asserted-by":"crossref","first-page":"c61","DOI":"10.1159\/000088932","article-title":"Long-term efficacy and tolerability of lanthanum carbonate: Results from a 3-year study","volume":"102","author":"Hutchison","year":"2006","journal-title":"Nephron Clin Pract"},{"key":"10.1053\/j.ajkd.2009.06.004_bib64","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/sj.ki.5001932","article-title":"Cognitive function in stage 5 chronic kidney disease patients on hemodialysis: No adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy","volume":"71","author":"Altmann","year":"2007","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2009.06.004_bib65","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.ahj.2004.07.023","article-title":"Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients","volume":"149","author":"Ferramosca","year":"2005","journal-title":"Am Heart J"},{"key":"10.1053\/j.ajkd.2009.06.004_bib66","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1053\/j.ajkd.2007.12.002","article-title":"A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: A secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data","volume":"51","author":"St Peter","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2009.06.004_bib67","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2215\/CJN.00560206","article-title":"The case against calcium-based phosphate binders","volume":"1","author":"Moe","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2009.06.004_bib68","doi-asserted-by":"crossref","first-page":"704","DOI":"10.2215\/CJN.01831105","article-title":"Calcium-based phosphate binders are appropriate in chronic renal failure","volume":"1","author":"Friedman","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2009.06.004_bib69","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2215\/CJN.00950306","article-title":"Phosphate binders: Hold the calcium?","volume":"1","author":"Bushinsky","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2009.06.004_bib70","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/sj.ki.5002527","article-title":"The details bedevil DCOR","volume":"72","author":"Silver","year":"2007","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2009.06.004_bib71","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1056\/NEJMe0901067","article-title":"Sunset for statins after AURORA?","volume":"360","author":"Strippoli","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2009.06.004_bib72","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstr\u00f6m","year":"2009","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2009.06.004_bib73","first-page":"S230","article-title":"Caring for Australasians with Renal Impairment (CARI)","volume":"11","author":"Elder","year":"2006","journal-title":"Nephrology (Carlton)"},{"key":"10.1053\/j.ajkd.2009.06.004_bib74","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1053\/jarr.2003.50016","article-title":"Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients","volume":"10","author":"Burke","year":"2003","journal-title":"Adv Ren Replace Ther"},{"key":"10.1053\/j.ajkd.2009.06.004_bib75","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1523-1755.2004.00877.x","article-title":"A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States","volume":"66","author":"Manns","year":"2004","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2009.06.004_bib76","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1093\/ndt\/gfm421","article-title":"Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients","volume":"22","author":"Tonelli","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2009.06.004_bib77","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1093\/ndt\/gfm561","article-title":"Sevelamer: A promising but unproven drug","volume":"22","author":"Palmer","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2009.06.004_bib78","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006023","article-title":"Phosphate binders for preventing and treating bone and cardiovascular disease in chronic kidney disease patients (protocol)","volume":"2","author":"Navaneethan","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.ajkd.2009.06.004_bib79","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0140-6736(07)60165-2","article-title":"Haemoglobin targets: We were wrong, time to move on","volume":"369","author":"Strippoli","year":"2007","journal-title":"Lancet"},{"key":"10.1053\/j.ajkd.2009.06.004_bib80","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1053\/j.ajkd.2005.09.009","article-title":"Hypothesis versus association: The optimal hemoglobin target debate","volume":"46","author":"Strippoli","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2009.06.004_bib81","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/ki.2009.60","article-title":"Oral phosphate binders","volume":"75","author":"Hutchinson","year":"2009","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2009.06.004_bib82","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1185\/030079908X260853","article-title":"An economic evaluation of sevelamer in patients new to dialysis","volume":"24","author":"Taylor","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1053\/j.ajkd.2009.06.004_bib83","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1093\/ndt\/gfm367","article-title":"Economic evaluation of sevelamer in patients with end-stage renal disease","volume":"22","author":"Manns","year":"2007","journal-title":"Nephrol Dial Transplant"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638609008658?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638609008658?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T01:52:53Z","timestamp":1759456373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638609008658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":82,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["S0272638609008658"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2009.06.004","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benefits and Harms of Phosphate Binders in CKD: A Systematic Review of Randomized Controlled Trials","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2009.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}